2026년 10월 29일 더바이오 주요뉴스 [https://www.thebionews.net/edit/webzine.html?idxno=673](https://www.thebionews.net/edit/webzine.html?idxno=673) ● 삼성도 '비만약' 경쟁 참전…'월 1회 세마글루티드' 코드명 첫 명시 [https://www.thebionews.net/news/articleView.html?idxno=29586](https://www.thebionews.net/news/articleView.html?idxno=29586) ● 한미약품, 차세대 비만약 ‘UCN2·GLP-1’ 병용으로 체중·체성분↓ [https://www.thebionews.net/news/articleView.html?idxno=29583](https://www.thebionews.net/news/articleView.html?idxno=29583) ● 킴 팽 노보홀딩스 파트너 “中, 패스트 팔로어 넘어 ‘혁신신약 개발국’ 도약” [https://www.thebionews.net/news/articleView.html?idxno=29573](https://www.thebionews.net/news/articleView.html?idxno=29573) ● 삼성바이오로직스 “이중항체 개발, 물질별 전략 달라야…맞춤형 CMC로 승부” [https://www.thebionews.net/news/articleView.html?idxno=29580](https://www.thebionews.net/news/articleView.html?idxno=29580) ● “바이오기업은 파는 게 아니라, ‘인수되는 것’”…빅파마 M&A 성공 전략은 [https://www.thebionews.net/news/articleView.html?idxno=29611](https://www.thebionews.net/news/articleView.html?idxno=29611) ● “바이오딜, 좋은 데이터만으론 부족…‘상업 생산’이 성패 가른다” [https://www.thebionews.net/news/articleView.html?idxno=29621](https://www.thebionews.net/news/articleView.html?idxno=29621) ● 이슬기 디앤디파마텍 대표 “‘뉴코’, 자녀 결혼과 같아…매력적이지만 신중해야” [https://www.thebionews.net/news/articleView.html?idxno=29613](https://www.thebionews.net/news/articleView.html?idxno=29613) ● 오너3세 유원상 유유제약 대표 “고양이 신약 개발, 사람용 확장…수익 재투자” [https://www.thebionews.net/news/articleView.html?idxno=29619](https://www.thebionews.net/news/articleView.html?idxno=29619) ● 넥스아이, 설립 5년 만에 7개 파이프라인 확보…“기존 L/O 성과 뛰어넘을 것” [https://www.thebionews.net/news/articleView.html?idxno=29608](https://www.thebionews.net/news/articleView.html?idxno=29608) ● 메디포스트, 오원일·민호성 각자 대표 체제 전환…美 법인에 200억원 출자 [https://www.thebionews.net/news/articleView.html?idxno=29626](https://www.thebionews.net/news/articleView.html?idxno=29626) ● 아스텔라스, 豪 오닥스 ‘IL-12 면역항암제’ 확보 추진…최대 1.8조원 계약 [https://www.thebionews.net/news/articleView.html?idxno=29620](https://www.thebionews.net/news/articleView.html?idxno=29620) ● 대원제약, P-CAB 신약 후보 ‘파도프라잔’ 임상3상 성공…연내 품목허가 신청 [https://www.thebionews.net/news/articleView.html?idxno=29632](https://www.thebionews.net/news/articleView.html?idxno=29632) ● 강동경희대병원 류창우 진료부원장, 韓 스텐트리트리버 ‘울트리바’ 첫 시술 [https://www.thebionews.net/news/articleView.html?idxno=29578](https://www.thebionews.net/news/articleView.html?idxno=29578) ● GSK, 3Q 매출 16조원 전년比 5%↑…항암제 매출 23% 증가 [https://www.thebionews.net/news/articleView.html?idxno=29585](https://www.thebionews.net/news/articleView.html?idxno=29585) ● 씨엔알리서치·비티시너지, 역노화 마이크로바이옴 신소재 글로벌 임상 추진 [https://www.thebionews.net/news/articleView.html?idxno=29616](https://www.thebionews.net/news/articleView.html?idxno=29616) ● 셀트리온, 과징금 6.3억에 행정소송…“휴마시스와 분쟁, 하도급법 대상 아냐” [https://www.thebionews.net/news/articleView.html?idxno=29610](https://www.thebionews.net/news/articleView.html?idxno=29610) ● 아이진 컨소시엄, 코로나19 mRNA 백신 후보물질 임상1상 투여 개시 [https://www.thebionews.net/news/articleView.html?idxno=29593](https://www.thebionews.net/news/articleView.html?idxno=29593) ● JW중외제약, 내분비학회서 SGLT-2 기반 3제 신약 ‘엠파가드’ 3상 결과 발표 [https://www.thebionews.net/news/articleView.html?idxno=29609](https://www.thebionews.net/news/articleView.html?idxno=29609) ● 동구바이오제약, 30억원 규모 자사주 전량 소각…주주가치 제고 본격화 [https://www.thebionews.net/news/articleView.html?idxno=29590](https://www.thebionews.net/news/articleView.html?idxno=29590) ● 프로티나, 골관절염 파이프라인 글로벌 특허 확대…日 제약사 2곳과 L/O 논의 [https://www.thebionews.net/news/articleView.html?idxno=29597](https://www.thebionews.net/news/articleView.html?idxno=29597) ● Korea University Medicine teams up with Switzerland’s University of Basel on biotechnology commercialization [https://www.thebionews.net/news/articleView.html?idxno=29631](https://www.thebionews.net/news/articleView.html?idxno=29631) ● [ESMO] LigaChem Biosciences presents preclinical and clinical trial posters for CLDN18.2 ADC ‘LCB02A’ [https://www.thebionews.net/news/articleView.html?idxno=29630](https://www.thebionews.net/news/articleView.html?idxno=29630) ● Samsung Bioepis inks 10-year exclusive supply deal for rare disease treatment in Brazil [https://www.thebionews.net/news/articleView.html?idxno=29629](https://www.thebionews.net/news/articleView.html?idxno=29629) ● Oncology dominates 73 global Q3 technology transfers and partnerships, with Alteogen cases ranking at the top [https://www.thebionews.net/news/articleView.html?idxno=29628](https://www.thebionews.net/news/articleView.html?idxno=29628) ● Celltrion’s ‘Remsima’ ranks No. 1 in Japan with 48% market share – Sales expand in Asia and Latin America [https://www.thebionews.net/news/articleView.html?idxno=29627](https://www.thebionews.net/news/articleView.html?idxno=29627) ● EYEGENE consortium starts Phase 1 trial dosing for COVID-19 mRNA vaccine candidate [https://www.thebionews.net/news/articleView.html?idxno=29625](https://www.thebionews.net/news/articleView.html?idxno=29625) ● Gangdong Kyung Hee University Hospital's Medical Affairs VP Dr. Ryu Chang-woo, Performs First Procedure on Korean Stent Retriever ‘ULTRIVA’ [https://www.thebionews.net/news/articleView.html?idxno=29624](https://www.thebionews.net/news/articleView.html?idxno=29624) ● Humedix Hosts 2nd Annual Academic Exchange Program 'ACE' for Brazilian Medical Professionals [https://www.thebionews.net/news/articleView.html?idxno=29618](https://www.thebionews.net/news/articleView.html?idxno=29618) ● MEDIPOST rolls out service to build AOF stem cell banks on Korean chemical composition media [https://www.thebionews.net/news/articleView.html?idxno=29604](https://www.thebionews.net/news/articleView.html?idxno=29604) ● [ESMO] Vaxcellbio targets Phase 1 clinical trial filling for CAR-MIL ‘VCB-1201’ by June 2027 [https://www.thebionews.net/news/articleView.html?idxno=29603](https://www.thebionews.net/news/articleView.html?idxno=29603) *제약바이오 10월 29일 아침 유튜브 라디오 뉴스(매일 아침 업로드) [https://www.youtube.com/watch?v=qkPCmDwpemw](https://www.youtube.com/watch?v=qkPCmDwpemw)